On October 6, 2022 Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, reported that its onCARlytics (CF33-CD19) oncolytic virus technology will be featured in three abstracts at the renowned Annual Meeting for the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper), to be held in Boston, USA on 8-12 November 2022 (Press release, Imugene, OCT 6, 2022, View Source [SID1234621790]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Known as one of the most prestigious immunotherapy events on the calendar, SITC (Free SITC Whitepaper) 2022 will feature cuttingedge research presentations by various experts, oral, and poster abstract presentations and various opportunities for networking and discussion with members of the oncology community.
The abstract titles were released at 8am EDT (US Eastern Daylight Time) 5 October 2022, with those featuring Imugene’s onCARlytics as follows:
Title: Combination immunotherapy using a novel chimeric oncolytic virus to redirect CD19 bispecific T cell engagers to target solid tumors Abstract #: 305 Title: CF33-CD19t oncolytic virus (onCARlytics) targets hepatocellular carcinoma (HCC) and in combination with Artemis CD19 T cells results in significant tumor killing Abstract #: 368
Title: CF33-CD19t oncolytic virus (onCARlytics) in combination with off-the-shelf allogeneic CyCART-19 T cells targeting de novo CD19+ solid tumors Abstract #: 847
Imugene will announce further detail from these abstracts at the time of the event.
onCARlytics is a CD19-expressing oncolytic virus that enters tumour cells and forces them to express the CD19 protein on the cell surface, presenting a target for CD19 targeting therapies. Imugene exclusively IMUGENE LIMITED ACN 009 179 551 2 licensed the technology from City of Hope, one of the largest cancer research and treatment organisations in the US.